Director of Polymicrocaps,
Claudio Cerati has completed his Pharmaceutical degree from the University of Buenos Aires and post degree of Litentiate in Pharmaceutical Industry at the same university. Post graduate studies at PIAT (Pharmaceutical Industry Advanced Training )University of Manchester UK. He worked in research and development in pharmaceutical companies in Argentina, Colombia , Brasil and Costa Rica. He is author of several patents on drug delivery with cession of rights to the companies where he worked
Generic Drug development represents an increased field of interest from national and multinational pharmaceutical companies. since original patents expiry left an open window for these companies .Most active pharmaceutical ingredients are hydrophobic moieties and thus , dissolution stage represents a difficult problem to solve. From many years scientists have attempted to enhance dissolution by different chemical or physical means , examples of these technologies include:, physical reduction of particle size ,solubilization by micellar inclusion , liposome encapsulation, niosome technologies . Nanotechnology has opened a new window either for dissolution enhancement, drug absorption and final drug availability at the site of action. Drug absorption from different physiological barriers represents a second hurdle to overcame. Particle engineering by supercritical fluid crystallization , spherical crystallization and surface treatment by polymers represents an alternative either for inhalation delivery , oral and injectable delivery routes. New polymer associations ,increased functionalities and more strict regulations for excipients allows for the obtention of reproducible and reliable results on a long term basis. Amorphicity achieved on surfaces either from polymers , bulk excipients and active pharmaceutical ingredients can be used as a strategy for drug dissolution and included into new formulation design. It is interesting to note that R&D pharmacist must evaluate these technologies at the design stage not only to enhance bioavailability but to optimize drug delivery systems and either patenting them.